News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,344 Results
Type
Article (87450)
Company Profile (739)
Press Release (770137)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232781)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91187)
Employer Resources (205)
FDA (18264)
Job Trends (17422)
News (396888)
Policy (39847)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (121)
Alliances (56795)
ALS (153)
Alzheimer's disease (1750)
Antibody-drug conjugate (ADC) (315)
Approvals (18373)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (539)
Cancer (4287)
Cardiovascular disease (301)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (40)
Celiac Disease (1)
Cell therapy (760)
Cervical cancer (29)
Clinical research (76115)
Collaboration (1605)
Company closure (4)
Compensation (990)
Complete response letters (65)
COVID-19 (2928)
CRISPR (85)
C-suite (732)
Cystic fibrosis (143)
Data (5410)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (340)
Diagnostics (6976)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (163)
Drug shortages (19)
Duchenne muscular dystrophy (197)
Earnings (98006)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132809)
Executive appointments (824)
FDA (20627)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1269)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (932)
Government (5332)
Grass and pollen (4)
Guidances (277)
Healthcare (20779)
HIV (48)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (59)
Indications (80)
Infectious disease (3163)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (46)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10093)
Liver cancer (87)
Longevity (13)
Lung cancer (583)
Lymphoma (332)
Machine learning (41)
Management (66)
Manufacturing (715)
MASH (159)
Medical device (14421)
Medtech (14451)
Mergers & acquisitions (22744)
Metabolic disorders (1063)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (79)
Neuroscience (2893)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (521)
Opinion (325)
Ovarian cancer (150)
Pain (153)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (33)
Patents (394)
Patient recruitment (414)
Peanut (56)
People (66281)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23596)
Phase 2 (33122)
Phase 3 (24821)
Pipeline (4284)
Policy (287)
Postmarket research (3546)
Preclinical (10586)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (278)
Rare diseases (792)
Real estate (7422)
Recruiting (80)
Regulatory (28240)
Reports (63)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (72)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4324)
State (2)
Stomach cancer (15)
Supply chain (76)
Tariffs (76)
The Weekly (122)
Vaccines (1009)
Venture capital (92)
Weight loss (338)
Women's health (71)
Worklife (22)
Date
Today (57)
Last 7 days (473)
Last 30 days (1947)
Last 365 days (25348)
2026 (2384)
2025 (25583)
2024 (34059)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51120)
Australia (9002)
California (9730)
Canada (2476)
China (1055)
Colorado (306)
Connecticut (389)
Delaware (295)
Europe (116911)
Florida (1256)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (652)
India (56)
Indiana (445)
Iowa (21)
Japan (338)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1256)
Massachusetts (7309)
Michigan (244)
Minnesota (452)
Mississippi (5)
Missouri (78)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2550)
New Mexico (29)
New York (2552)
North Carolina (1411)
North Dakota (9)
Northern California (4773)
Ohio (257)
Oklahoma (18)
Oregon (51)
Pennsylvania (1871)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3750)
Tennessee (58)
Texas (1360)
United States (33803)
Utah (209)
Vermont (1)
Virginia (168)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (82)
858,344 Results for "gsk bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.
January 21, 2026
·
1 min read
·
Tristan Manalac
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated the partnership.
December 8, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.
January 20, 2026
·
2 min read
·
Tristan Manalac
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.
November 21, 2025
·
3 min read
·
Tristan Manalac
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
January 7, 2026
·
2 min read
·
Tristan Manalac
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.
February 2, 2026
·
3 min read
·
Heather McKenzie
Press Releases
OCHRE BIO COMPLETES HUMAN LIVER FUNCTIONAL GENOMICS AND SINGLE-CELL DATASETS IN PARTNERSHIP WITH GSK
November 18, 2025
·
2 min read
1 of 85,835
Next
